Updates -Smoldering Multiple Myeloma from ASH 2025 | Rahul Banerjee, MD, FACP

Anito-cel (a BCMA CAR-T) : Shows No Cases of Delayed Neurotoxicity | Natalie Callander, MD

S100A8 -a new target to prevent T cell exhaustion BsAbs in myeloma | Adolfo Aleman, PhD

Fewer Bone Marrow Biopsies? Using Blood & Whole Genome Sequencing | Chrissy Baker, MSc

Making CAR-T Cells inside the body? inMMyCAR Trial Insights | Natalie Callander, MD

Does MGIP represent the earliest stage of myeloma? | Sungjae Kim, PhD

Etentamig in patients with relapsed refractory amyloidosis | Rajshekhar Chakraborty, MD

Update on Arlo-Cel, a GPRC5D CAR-T, in RRMM | Ciara Freeman, MD, PhD

AI Using Multimodal Datasets to Predict Response to CAR-T Treatment | Ciara Freeman, MD, PhD

Prophylactic Tocilizumab to Prevent CRS During Bispecific Step-up Dosing | Astrid Torpe, MD

MajesTEC-3 Late-Breaking Trial Results | Luciano Costa, MD

Promising Therapy for Hard-to-treat DLBCL: Epcoritamab + GemOx #DLBCL | Joshua Brody, MD

Highlights of Relapsed/Refractory Multiple Myeloma | Mohamad Mohty, MD, PhD

Highlights of Newly Diagnosed Multitple Myeloma | Mohamad Mohty, MD, PhD

Can Linvoseltamab Be Safely Combined with Anti-CD38 Antibodies? | Meletios Dimopoulos, MD

What I Learned at ASH as a Myeloma Patient: Personalized Care & Access | Valarie Traynham

Defining Functional High-Risk Myeloma & Why Its Important | Barry Paul, MD & Todd Kennedy

Join the Nutrivention 2 Study: Investigating a Plant Based Diet for MGUS or Smoldering Myeloma | Urvi Shah, MD

Highlights of Smoldering Multiple Myeloma from ASH25 | Mohamad Mohty, MD, PhD

Long-term PFS updates on the CARTITUDE-4 Trial | Luciano Costa, MD